Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › FL › Kissimmee › NPI 1689621450
Hospital

Osceola Regional Hospital, INC.

Osceola Regional Hospital, INC. was paid $18.49M by Medicaid between Jan 2018 and Dec 2024, across 213 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.

33Billing provider infoOSCEOLA REGIONAL HOSPITAL, INC.
KISSIMMEE, FL 34741
33aNPI1689621450assigned 05/27/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$18.49M
24GClaims720,612
24DCodes billed213
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in Florida

Rank by total paid#19 of 163
Median peer was paid$4.77M
This provider vs. median3.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$200K$400K$600K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201856,085$585K
2019157,521$2.32M
2020121,622$1.90M
2021144,892$3.80M
2022145,143$5.17M
202371,877$3.27M
2024incomplete23,472$1.45M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99283 Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity 35% 73,849 68,067 $6.48M
99284 Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity 18% 43,421 38,159 $3.27M
99282 Emergency department visit for the evaluation and management, low to moderate severity 6.6% 14,879 14,028 $1.22M
74177 Computed tomography, abdomen and pelvis; with contrast material 3.6% 4,195 3,827 $667K
80053 Comprehensive metabolic panel 3.2% 30,040 25,550 $598K
70450 Computed tomography, head or brain; without contrast material 2.8% 6,550 5,530 $525K
99285 Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life 2.8% 8,582 7,285 $518K
74176 Computed tomography, abdomen and pelvis; without contrast material 2.4% 3,576 3,235 $444K
80048 Basic metabolic panel (calcium, ionized) 2.4% 16,782 13,691 $435K
99281 Emergency department visit for the evaluation and management, self-limited or minor 2.0% 3,695 3,487 $364K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 1.7% 6,367 5,975 $311K
96361 Intravenous infusion, hydration; each additional hour 1.2% 3,129 2,821 $216K
201 more codes
71275 Computed tomographic angiography, chest, with contrast material 1.1% 1,601 $211K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion 1.1% 4,784 $206K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance <1% 21,969 $174K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 1,553 $164K
97597 <1% 4,435 $134K
80306 <1% 7,180 $129K
87070 <1% 8,259 $124K
G0378 Hospital observation service, per hour <1% 9,479 $114K
72125 Computed tomography, cervical spine; without contrast material <1% 2,634 $114K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 10,898 $112K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 17,424 $106K
71046 Radiologic examination, chest; 2 views <1% 6,645 $88K
71045 Radiologic examination, chest; single view <1% 15,456 $81K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 1,421 $81K
78452 Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress <1% 438 $64K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 948 $59K
84702 <1% 5,992 $56K
81025 <1% 10,528 $50K
81003 <1% 18,103 $48K
85027 <1% 51,284 $48K
87086 Culture, bacterial; quantitative colony count, urine <1% 4,985 $45K
94640 Pressurized or nonpressurized inhalation treatment for acute airway obstruction <1% 1,903 $41K
G0283 Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care <1% 161 $41K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 2,168 $40K
76818 <1% 1,553 $39K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 1,803 $38K
76801 <1% 2,664 $35K
11042 Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm <1% 869 $35K
97163 <1% 1,046 $33K
76830 Ultrasound, transvaginal <1% 1,831 $32K
87210 <1% 5,167 $32K
74018 <1% 1,267 $31K
58661 <1% 103 $31K
12001 <1% 548 $29K
73610 <1% 1,545 $28K
76805 Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation <1% 1,406 $27K
A9270 Non-covered item or service <1% 9,800 $27K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 16,128 $27K
73130 <1% 1,559 $26K
73562 <1% 1,624 $25K
72131 <1% 1,270 $22K
73030 <1% 1,423 $20K
81001 <1% 5,215 $19K
80047 <1% 1,503 $19K
12011 <1% 302 $19K
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 1,523 $19K
73630 <1% 1,573 $18K
84484 <1% 12,228 $17K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 7,816 $17K
C1769 Guide wire <1% 590 $16K
87430 <1% 9,009 $15K
84703 <1% 9,764 $14K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 8,723 $14K
73110 <1% 853 $14K
G0463 Hospital outpatient clinic visit for assessment and management of a patient <1% 866 $13K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 1,922 $13K
C1894 Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser <1% 571 $13K
70486 <1% 361 $12K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 2,636 $12K
85610 <1% 6,710 $11K
93017 <1% 521 $11K
86850 <1% 2,323 $10K
93971 <1% 687 $10K
87040 <1% 1,681 $10K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 1,062 $10K
85730 <1% 5,307 $9K
83735 <1% 6,511 $8K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 4,327 $8K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 1,550 $8K
72100 <1% 912 $8K
J7030 Infusion, normal saline solution , 1000 cc <1% 16,476 $8K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 1,415 $8K
10060 <1% 121 $7K
87807 <1% 1,770 $7K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 11,592 $6K
80076 <1% 1,946 $6K
72128 <1% 567 $6K
73080 <1% 330 $5K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 1,617 $5K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 7,668 $5K
J1644 Injection, heparin sodium, per 1000 units <1% 452 $5K
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 576 $5K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 4,337 $5K
73090 <1% 558 $5K
00840 <1% 569 $5K
76775 <1% 172 $4K
97116 <1% 983 $4K
86900 <1% 3,703 $4K
97035 <1% 25 $4K
J1815 Injection, insulin, per 5 units <1% 2,030 $4K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 6,373 $4K
83880 <1% 2,847 $4K
96375 Therapeutic injection; each additional sequential IV push <1% 8,107 $3K
84112 <1% 231 $3K
80061 Lipid panel <1% 2,124 $3K
J7050 Infusion, normal saline solution, 250 cc <1% 304 $3K
80320 <1% 543 $3K
73590 <1% 438 $3K
84443 Thyroid stimulating hormone (TSH) <1% 2,992 $3K
83036 Hemoglobin; glycosylated (A1C) <1% 2,357 $3K
70496 <1% 29 $3K
12002 <1% 52 $3K
J1650 Injection, enoxaparin sodium, 10 mg <1% 1,909 $3K
85379 <1% 2,326 $3K
29125 <1% 101 $3K
99152 <1% 288 $2K
J2704 Injection, propofol, 10 mg <1% 453 $2K
93458 <1% 16 $2K
74022 <1% 72 $2K
82550 <1% 1,685 $2K
82731 <1% 113 $2K
83690 <1% 9,899 $2K
82553 <1% 852 $2K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,735 $2K
73502 <1% 140 $2K
82247 <1% 235 $2K
72040 <1% 135 $2K
C1729 Catheter, drainage <1% 29 $2K
58558 <1% 17 $1K
77067 Screening mammography, bilateral, including computer-aided detection <1% 72 $1K
96376 <1% 2,087 $1K
72170 <1% 224 $1K
74021 <1% 53 $1K
88304 <1% 150 $1K
J2270 Injection, morphine sulfate, up to 10 mg <1% 4,952 $1K
93970 <1% 146 $1K
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 2,315 $1K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 147 $1K
C1725 Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) <1% 17 $1K
83605 <1% 1,846 $1K
A9500 Technetium tc-99m sestamibi, diagnostic, per study dose <1% 463 $986.50
86140 <1% 893 $985.50
J0690 Injection, cefazolin sodium, 500 mg <1% 187 $868.57
85014 <1% 34 $844.03
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 4,229 $837.62
97162 <1% 63 $829.82
84132 <1% 499 $827.71
J1170 Injection, hydromorphone, up to 4 mg <1% 139 $820.27
82248 <1% 1,761 $816.06
J2785 Injection, regadenoson, 0.1 mg <1% 288 $762.70
86901 <1% 3,679 $676.89
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 20 $676.06
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 1,035 $675.29
43239 Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple <1% 28 $626.71
82330 <1% 46 $610.74
J7120 Ringers lactate infusion, up to 1000 cc <1% 1,808 $582.94
71250 <1% 30 $540.12
84100 <1% 633 $507.57
J2060 Injection, lorazepam, 2 mg <1% 647 $503.02
J0360 Injection, hydralazine hcl, up to 20 mg <1% 65 $491.98
82077 <1% 1,297 $488.29
82570 <1% 317 $442.76
87147 <1% 173 $375.32
73060 <1% 63 $356.45
85651 <1% 651 $341.21
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 3,518 $340.43
82272 <1% 28 $287.26
70498 <1% 32 $283.53
82803 <1% 121 $277.18
84145 <1% 197 $275.64
76819 Fetal biophysical profile; without non-stress testing <1% 12 $274.29
86308 <1% 14 $271.69
72190 <1% 110 $231.26
75574 <1% 14 $206.21
J0500 Injection, dicyclomine hcl, up to 20 mg <1% 27 $180.00
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 1,799 $173.56
97166 <1% 22 $148.39
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 451 $96.47
84439 <1% 25 $90.15
00731 <1% 12 $90.00
88307 <1% 112 $69.94
90715 <1% 64 $39.71
97535 Self-care/home management training, each 15 minutes <1% 94 $26.31
Q0177 Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen <1% 224 $24.21
G1003 Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program <1% 228 $21.65
82947 <1% 30 $10.29
84295 <1% 27 $7.35
84156 <1% 266 $6.49
J2800 Injection, methocarbamol, up to 10 ml <1% 512 $6.48
83615 <1% 424 $2.95
84550 <1% 333 $1.48
S0119 Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) <1% 2,802 $1.36
J8540 Dexamethasone, oral, 0.25 mg 0% 166 $0.00
73552 0% 13 $0.00
88342 0% 34 $0.00
A6257 Transparent film, sterile, 16 sq. in. or less, each dressing 0% 19 $0.00
72072 0% 13 $0.00
00952 0% 43 $0.00
J0561 Injection, penicillin g benzathine, 100,000 units 0% 14 $0.00
J0456 Injection, azithromycin, 500 mg 0% 14 $0.00
J3475 Injection, magnesium sulfate, per 500 mg 0% 41 $0.00
97167 0% 66 $0.00
L0140 Cervical, semi-rigid, adjustable (plastic collar) 0% 13 $0.00
90714 0% 71 $0.00
85396 0% 14 $0.00
73140 0% 56 $0.00
88302 0% 83 $0.00
C1758 Catheter, ureteral 0% 28 $0.00
C9113 Injection, pantoprazole sodium, per vial 0% 53 $0.00
86703 0% 13 $0.00
S0028 Injection, famotidine, 20 mg 0% 29 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBIGGAR, CARRIE (CFO)